Healthcare, Regulatory and Reimbursement Landscape - Philippines

NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Healthcare, Regulatory and Reimbursement Landscape - Philippines

http://www.reportlinker.com/p0886904/Healthcare-Regulatory-and-Reimbursement-Landscape---Philippines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Healthcare, Regulatory and Reimbursement Landscape - Philippines

Summary

GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Philippines". The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of Philippines. The report identifies the key trends in the healthcare market of Philippines. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Philippines. Most importantly, the report provides valuable insights on the trends and segmentation of pharmaceutical market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts.

The population of Philippines in 2010 was approximately 94 million and was the 12th most populated country in the world. The increase in the population is primarily due to high birth rate and increase in life expectancy. An increasing elderly population is a matter of concern for the policy planners of Philippines. The pharmaceutical market in Philippines was $3 billion in 2010 and is expected to reach approximately $7.4 billion by 2020 at a projected CAGR of 9.4%.

The positive trend in the healthcare market of Philippines can be attributed primarily to -

- Generic substitution in both public and private sectors is a driver for manufacturing of generic drugs in Philippines

- Increased expenditure on medicines by Local Government Units

- Initiatives of the government for the prevention and management of chronic diseases

- Improved and updated regulatory environment

Scope

The report provides information on the healthcare, regulatory and reimbursement landscape of Philippines. The scope includes -

- Overview of the pharmaceutical market of Philippines including the market size, market segmentation, key drivers and barriers for the market.

- Profile and SWOT analysis of the major players in the pharmaceutical. Key players covered for the pharmaceutical market are United Laboratories, Pfizer, GlaxoSmithKline, Abbott Laboratories and Novartis.

- Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, regulatory agencies and market authorization process for new drug and medical devices for Philippines.

- A detailed analysis of the political and economic environment of Philippines including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.

- An overview of the opportunities and challenges for growth that exist in the healthcare market of Philippines.

Reasons to buy

The report on Philippines comprehensively covers the pharmaceutical market of Philippines. The report will enhance your decision making capability. It will allow you to -

- Develop business strategies by understanding the trends shaping and driving the healthcare market of Philippines.

- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the Philippine healthcare market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- Identify, understand and capitalize on the opportunities and challenges in the healthcare market of Philippines.

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 10

2.1 Report Guidance 10

3 Overview of Pharmaceutical and Medical Device Market 11

3.1 Pharmaceutical Market 11

3.1.1 Market Overview 11

3.1.2 Supply Channels 14

3.1.3 Market Segments 16

3.1.4 Overview of Major Disease Areas 19

3.1.5 Major Players 20

3.2 Market Drivers and Barriers 46

3.2.1 Drivers 46

3.2.2 Barriers 46

4 Market Access 47

4.1 Reimbursement and Payer Landscape 47

4.1.1 Overview of Healthcare system 47

4.1.2 Reimbursement Process 48

4.1.3 Overview of Insurance Providers 51

4.1.4 Patient Share in Healthcare Spending 55

4.1.5 Price Trends in the Healthcare Sector 56

4.1.6 Pricing Policies 56

4.2 Regulatory Landscape 58

4.2.1 Overview of Regulatory Agencies 58

4.2.2 Market Authorization Procedure for Pharmaceutical Products 58

4.2.3 New Medical Device Approval Process 63

4.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing 64

4.2.5 Exports and Imports 65

4.2.6 Intellectual Property Rights 66

4.2.7 Clinical Trial Regulations 69

4.2.8 Pharmaceutical Advertising Regulations 70

4.2.9 Pharmacy Regulations 71

4.2.10 Labeling and Packaging Regulations 72

5 Country Analysis 73

5.1 Political Environment 73

5.1.1 Political Structure 73

5.1.2 Analysis of Current Political Environment 73

5.1.3 Healthcare Policy Initiatives 74

5.2 Economic Landscape 76

5.3 Economic Indicators 78

5.3.1 Gross Domestic Product 78

5.3.2 Gross National Income 84

5.3.3 Inflation 85

5.3.4 Currency Exchange Rate 88

5.3.5 Foreign Direct Investment 89

5.3.6 Foreign Exchange Reserves 90

5.3.7 Trade Balance 91

5.3.8 Fiscal Deficit 93

5.3.9 General Government Gross Debt 94

5.3.10 External Debt 95

5.3.11 Major Industries 96

5.4 Demographics 98

5.4.1 Population 98

5.4.2 Education and Literacy 116

5.4.3 Employment 117

5.4.4 Disease Burden 118

5.5 Healthcare Infrastructure 121

5.5.1 Healthcare Facilities 121

5.5.2 Healthcare Parameters 126

5.5.3 Environmental Health 127

5.5.4 Healthcare Personnel 129

5.6 Healthcare Expenditure 130

5.6.1 Overview 130

5.6.2 Major components of Healthcare Spending 131

5.6.3 Share of Public and Private Sector 132

5.6.4 Spending in Pharmaceutical R&D 133

5.7 Trade Associations 134

5.7.1 Pharmaceutical and Healthcare Association of the Philippines (PHAP) 134

5.7.2 The Philippine Pharmaceutical Manufacturers Association (PPMA) 134

5.7.3 The Philippine Pharmacist Association (PPha) 134

5.7.4 The Philippine Medical Association (PMA) 134

5.8 Trade Fairs 135

6 Opportunities and Challenges 136

6.1 Opportunities 136

6.2 Challenges 136

7 Appendix 138

7.1 Abbreviations 138

7.2 Bibliography 140

7.3 Methodology 145

7.3.1 Coverage 145

7.3.2 Secondary Research 146

7.3.3 Forecasting 146

7.3.4 Primary Research 146

7.3.5 Expert Panel Validation 146

7.4 Contact Us 147

7.5 Disclaimer 147

List of Tables

Table 1: Pharmaceutical Market ($bn), The Philippines, 2005–2010 12

Table 2: Pharmaceutical Market ($bn), The Philippines, Forecast, 2011–2020 13

Table 3: Price Distribution of Pharmaceuticals for Multinational Companies (%), 2008 15

Table 4: Drugs Going Off-Patent, Revenues ($bn), Global, 2011–2014 17

Table 5: Major Products, Pfizer, Global, Revenue ($m), 2011 24

Table 6: Late Stage Pipeline, Pfizer, 2012 25

Table 7: Major Products, GlaxoSmithKline, Global, Revenue ($m), 2011 30

Table 8: Late Stage Pipeline, GlaxoSmithKline, 2012 30

Table 9: Major Products, Abbott, Global, Revenue ($m), 2011 35

Table 10: Late Stage Pipeline, Abbott, 2011 36

Table 11: Major Products , Novartis, Global, Revenue ($m), 2011 39

Table 12: Planned Filings, Novartis, 2012 ?2016 39

Table 13: Membership in PhilHealth, The Philippines, Sectors Share (%), 2010 53

Table 14: Benefit Payments from PhilHealth, The Philippines, Sector Share (%), 2010 54

Table 15: Healthcare Spending, The Philippines, Out-of-pocket expenditure (%), 2005–2010 55

Table 16: Change in Average Price of Health Sector (%), The Philippines, 2006–2011 56

Table 17: GDP Per Capita ($), The Philippines, 2005–2010 78

Table 18: GDP Per Capita ($), The Philippines, Forecast, 2011–2020 79

Table 19: GDP ($bn), The Philippines, 2005–2010 80

Table 20: GDP ($bn), The Philippines, Forecast, 2011–2020 81

Table 21: GDP, The Philippines, Annual Growth (%), 2005–2010 82

Table 22: GDP, The Philippines, Annual Growth (%), 2011–2020 83

Table 23: GNI Per Capita ($), The Philippines, 2005–2010 84

Table 24: Average Consumer Price Index, The Philippines, 2005–2010 85

Table 25: Average Consumer Price, The Philippines, Annual Change (%), 2005–2010 86

Table 26: Average Consumer Price, The Philippines, Annual Change (%), 2011–2020 87

Table 27: Currency Exchange Rate (PHP/$), The Philippines, 2006–2011 88

Table 28: Foreign Direct Investment ($bn), The Philippines, 2005–2010 89

Table 29: Foreign Exchange Reserves ($bn), The Philippines, 2005–2010 90

Table 30: Exports of Goods and Services ($bn), The Philippines, 2005–2010 91

Table 31: Imports of Goods and Services ($bn), The Philippines, 2005–2010 92

Table 32: Fiscal Deficit (% of GDP), The Philippines, 2005–2010 93

Table 33: General Government Gross Debt ($bn), The Philippines, 2005–2010 94

Table 34: External Debt ($bn), The Philippines, 2005–2010 95

Table 35: Major Industries, Industrial Sector, The Philippines, Gross Value Added ($bn), 2009–2010 96

Table 36: Major Industries, Service Sector, The Philippines, Gross Value Added ($bn), 2009–2010 97

Table 37: Population (m), The Philippines, 2005–2010 98

Table 38: Population (m), The Philippines, Forecast, 2011–2020 99

Table 39: Urban and Rural Population, The Philippines, Share (%), 2005–2010 100

Table 40: Urban and Rural Population, The Philippines, Share (%), Forecast, 2011–2020 101

Table 41: Age Groups, The Philippines, Population Distribution (%), 2005–2010 102

Table 42: Age Groups, The Philippines, Population Distribution (%), Forecast, 2011–2020 103

Table 43: Births (Per 1000 Population), The Philippines, 2005–2010 104

Table 44: Births (Per 1000 Population), The Philippines, 2011–2020 105

Table 45: Mortality (Per 1000 Population), The Philippines, 2005–2010 106

Table 46: Major Causes of Mortality ('000s), The Philippines, 2008 107

Table 47: Infant Mortality, The Philippines, Mortality Rate (Per 1,000 Live Births), 2005–2010 108

Table 48: Immunization Rate for DTP, Measles (%), The Philippines, 2005–2010 109

Table 49: Major Causes of Male Mortality ('000s), The Philippines, 2008 110

Table 50: Major Causes of Female Mortality ('000s), The Philippines, 2008 111

Table 51: Maternal Mortality (Per 100,000 Live Births), The Philippines, 2005, 2006, 2008 112

Table 52: Gender Ratio (M/F), The Philippines, 2005–2010 113

Table 53: Life Expectancy at Birth (Years), The Philippines, 2005–2010 114

Table 54: Life Expectancy at Birth (Years), The Philippines, Forecast, 2011–2020 115

Table 55: Students, The Philippines, Gross Enrolment (%), 2005–2010 116

Table 56: Unemployment Rate (%), The Philippines, 2005–2010 117

Table 57: Major Diseases, The Philippines, Morbidity ('000s), 2008 119

Table 58: Major Diseases, The Philippines, DALY (Per 100,000 Population), 2004 120

Table 59: Hospitals, The Philippines, 2005–2010 122

Table 60: Barangay Health Stations, The Philippines, 2005–2010 123

Table 61: Hospitals by Standard of Care, The Philippines, 2007 124

Table 62: Diagnostic Equipment (per 100,000 Population), The Philippines, 2007–2009 125

Table 63: Hospital Beds (Per 10,000 Population), The Philippines, 2005–2010 126

Table 64: CO2 (kilotons), The Philippines, 2005–2008 127

Table 65: PM10 (Micrograms Per Cubic Meter), The Philippines, 2005–2010 128

Table 66: Healthcare Personnel (Per 10,000 Population), The Philippines, 2007 129

Table 67: Healthcare Expenditure (% of GDP), The Philippines, 2005–2010 130

Table 68: Healthcare Expenditure, The Philippines, Share of Major Components (%), 2007 131

Table 69: Healthcare Expenditure, The Philippines, Public-Private Sector (%), 2005–2010 132

Table 70: Biomedical R&D Expenditure ($m), The Philippines, 2005–2007 133

Table 71: Major Healthcare Trade Fairs, The Philippines, 2012 13

List of Figures

Figure 1: Pharmaceutical Market ($bn), The Philippines, 2005–2010 12

Figure 2: Pharmaceutical Market ($bn), The Philippines, Forecast, 2011–2020 13

Figure 3: Pharmaceutical Distribution Channel, Distribution Share (%), The Philippines, 2008 14

Figure 4: Price Distribution of Pharmaceuticals for Multinational Companies (%), 2008 15

Figure 5: Drivers and Barriers, Healthcare Market, The Philippines, 2012 46

Figure 6: Healthcare System, The Philippines, 2012 47

Figure 7: Drug Selection Procedure for PNDF, The Philippines, 2012 49

Figure 8: Reimbursement Process, The Philippines, 2012 50

Figure 9: PhilHealth Milestones, The Philippines, 2012 52

Figure 10: Membership in PhilHealth, The Philippines, Sector Share (%), 2010 53

Figure 11: Benefit Payments from PhilHealth, The Philippines, Sector Share (%), 2010 54

Figure 12: Healthcare Spending, The Philippines, Out-of-pocket expenditure (%), 2005–2010 55

Figure 13: Change in Average Price of Health Sector (%), The Philippines, 2006–2011 56

Figure 14: FDA Structure, The Philippines 58

Figure 15: Approval Process of New Drugs and Medical Devices, The Philippines, 2012 60

Figure 16: Approval Process of Generic Drugs, The Philippines, 2012 62

Figure 17: Bureau of Health Devices and Technology Structure, The Philippines, 2012 63

Figure 18: Licensing Process for Manufacture of Pharmaceuticals and Medical Devices, The Philippines, 2012 64

Figure 19: Patent Approval Process, The Philippines, 2012 67

Figure 20: Trademark Approval Process, The Philippines, 2012 68

Figure 21: Procedure for Opening a Retail Pharmacy, The Philippines, 2012 71

Figure 22: Major Health Reforms, The Philippines, 1999–2009 75

Figure 23: GDP Per Capita ($), The Philippines, 2005–2010 78

Figure 24: GDP Per Capita ($), The Philippines, Forecast, 2011–2020 79

Figure 25: GDP ($bn), The Philippines, 2005–2010 80

Figure 26: GDP ($bn), The Philippines, Forecast, 2011–2020 81

Figure 27: GDP, The Philippines, Annual Growth (%), 2005–2010 82

Figure 28: GDP, The Philippines, Annual Growth (%), 2011–2020 83

Figure 29: GNI Per Capita ($), The Philippines, 2005–2010 84

Figure 30: Average Consumer Price Index, The Philippines, 2005–2010 85

Figure 31: Average Consumer Price, The Philippines, Annual Change (%), 2005–2010 86

Figure 32: Average Consumer Price, The Philippines, Annual Change (%), 2011–2020 87

Figure 33: Currency Exchange Rate (PHP/$), The Philippines, 2006–2011 88

Figure 34: Foreign Direct Investment ($bn), The Philippines, 2005–2010 89

Figure 35: Foreign Exchange Reserves ($bn), The Philippines, 2005–2010 90

Figure 36: Exports of Goods and Services ($bn), The Philippines, 2005–2010 91

Figure 37: Imports of Goods and Services ($bn), The Philippines, 2005–2010 92

Figure 38: Fiscal Deficit (% of GDP), The Philippines, 2005–2010 93

Figure 39: General Government Gross Debt ($bn), The Philippines, 2005–2010 94

Figure 40: External Debt ($bn), The Philippines, 2005–2010 95

Figure 41: Major Industries, Industrial Sector, The Philippines, Gross Value Added ($bn), 2009–2010 96

Figure 42: Major Industries, Service Sector, The Philippines, Gross Value Added ($bn), 2009–2010 97

Figure 43: Population (m), The Philippines, 2005–2010 98

Figure 44: Population (m), The Philippines, Forecast, 2011–2020 99

Figure 45: Urban and Rural Population, The Philippines, Share (%), 2005–2010 100

Figure 46: Urban and Rural Population, The Philippines, Share (%), Forecast, 2011–2020 101

Figure 47: Age Groups, The Philippines, Population Distribution (%), 2005–2010 102

Figure 48: Age Groups, The Philippines, Population Distribution (%), Forecast, 2011–2020 103

Figure 49: Births (Per 1000 Population), The Philippines, 2005–2010 104

Figure 50: Births (Per 1000 Population), The Philippines, 2011–2020 105

Figure 51: Mortality (Per 1000 Population), The Philippines, 2005–2010 106

Figure 52: Major Causes of Mortality ('000s), The Philippines, 2008 107

Figure 53: Infant Mortality, The Philippines, Mortality Rate (Per 1,000 Live Births), 2005–2010 108

Figure 54: Immunization Rate for DTP, Measles (%), The Philippines, 2005–2010 109

Figure 55: Major Causes of Male Mortality ('000s), The Philippines, 2008 110

Figure 56: Major Causes of Female Mortality ('000s), The Philippines, 2008 111

Figure 57: Maternal Mortality (Per 100,000 Live Births), The Philippines, 2005, 2006, 2008 112

Figure 58: Gender Ratio (M/F), The Philippines, 2005–2010 113

Figure 59: Life Expectancy at Birth (Years), The Philippines, 2005–2010 114

Figure 60: Life Expectancy at Birth (Years), The Philippines, Forecast, 2011–2020 115

Figure 61: Students, The Philippines, Gross Enrolment (%), 2005–2010 116

Figure 62: Unemployment Rate (%), The Philippines, 2005–2010 117

Figure 63: Major Diseases, The Philippines, Morbidity ('000s), 2008 119

Figure 64: Major Diseases, The Philippines, DALY (Per 100,000 Population), 2004 120

Figure 65: Hospitals, The Philippines, 2005–2010 122

Figure 66: Barangay Health Stations, The Philippines, 2005–2010 123

Figure 67: Hospitals by Standard of Care, The Philippines, 2007 124

Figure 68: Diagnostic Equipment (per 100,000 Population), The Philippines, 2007–2009 125

Figure 69: Hospital Beds (Per 10,000 Population), The Philippines, 2005–2010 126

Figure 70: CO2 (kilotons), The Philippines, 2005–2008 127

Figure 71: PM10 (Micrograms Per Cubic Meter), The Philippines, 2005–2010 128

Figure 72: Healthcare Personnel (Per 10,000 Population), The Philippines, 2007 129

Figure 73: Healthcare Expenditure (% of GDP), The Philippines, 2005–2010 130

Figure 74: Healthcare Expenditure, The Philippines, Share of Major Components (%), 2007 131

Figure 75: Healthcare Expenditure, The Philippines, Public-Private Sector (%), 2005–2010 132

Figure 76: Biomedical R&D Expenditure ($m), The Philippines, 2005–2007 133

Figure 77: Opportunities and Challenges, Healthcare Market, The Philippines, 2012 137

To order this report:

: Healthcare, Regulatory and Reimbursement Landscape - Philippines

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker